2Oh TS, Lee O, Kim JE, et al. Quantitative method for measuring ther- apeutic efficacy of the 308 nm excimer laser for vitiligo[ J~. Skin Res Technol,2012,18 ( 3 ) : 347 - 355.
3Ezzedine K, Diallo A, L6aut6-Labr~ze C, et al. Halo naevi and leu- kotrichia are strong predictors of the passage to mixed vitiligo in a subgroup of segmental vitiligo [ J 1. Br J Dermatol, 2012, 166 ( 3 ) : 539 - 544.
4Alghamdi KM, Khurram H, TaYeb A. Survey of dermatologists' photo- therapy practices for vitiligo[ J ]. Indian J Dermatol Venereol Leprol, 9012,75(1) :74 -81.
5Nordal E J, Guleng GE, Ronnevig JR. Treatment of vitiligo with nar- rowband-UVB (TL01) combined with tacrolimus ointment (0.1% ) vs. placebo ointment, a randomized fight/left double-blind compara-tive study[J]. J Eur Acad Dermatol Venereol,2011,25 (12) :1440 - 1443.
6Kathuria S, Khaitan BK, Ramam M, et al. Segmental vitiligo : a ran- domized controlled trial to evaluate efficacy and safety of 0.1% ta- crolimus ointment vs 0.05% fluticasone propionate cream[ J]. Indi- an J Dermatol Venereol Lepro1,2012 ,78 ( 1 ) :68 - 73.
7Schallreuter KU, Salem MA, Gibbons NC, et al. Blunted epidermal L-tryptophan metabolism in vitiligo affects immune response and R.OS scavenging by Fenton chemistry, part 2: Epidermal H202/ ONOO--mediated stress in vitiligo hampers indoleamine 2,3-dioxy- genase and aryl hydrocarbon receptor-mediated immune response sig- naling[J]. FASEB J ,2012,26(6) :2471 -2485.
8Zloza A, Lyons GE, Chlewicki LK, et al. Engagement of NK receptor NKG2D, but not 2B4, results in self-reactive CD8 +T ceils and auto- immune vitiligo [ J ]. Autoimmunity, 2011,44 ( 8 ) : 599 - 606.
